Abtan Jérémie, Bhatt Deepak L, Elbez Yedid, Sorbets Emmanuel, Eagle Kim, Reid Christopher M, Baumgartner Iris, Wu David, Hanson Mary E, Hannachi Hakima, Singhal Puneet K, Steg Philippe Gabriel, Ducrocq Gregory
FACT (French Alliance for Cardiovascular Trials), French Clinical Research Infrastructure Network, University Hospital Departments-FIRE, Hôpital Bichat, Public Assistance Hospitals of Paris, Paris Diderot University, Sorbonne University Paris Cité, and National Institute of Health and Medical Research, U-1148 Paris, France.
Heart and Vascular Center, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
Clin Cardiol. 2017 Sep;40(9):710-718. doi: 10.1002/clc.22721. Epub 2017 May 18.
Patients with symptomatic peripheral artery disease (PAD) are at high risk of ischemic events. However, data about predictors of this risk are limited.
We analyzed baseline characteristics and 4-year follow-up of patients enrolled in the international REduction of Atherothrombosis for Continued Health (REACH) Registry with symptomatic PAD and no history of stroke/transient ischemic attack to describe annual rates of recurrent ischemic events globally and geographically.
The primary outcome was systemic ischemic events (composite of cardiovascular death, myocardial infarction, or stroke) at 4 years. The secondary outcome was limb ischemic events (composite of lower limb amputation, peripheral bypass graft, and percutaneous intervention for PAD) at 2 years. Multivariate analysis identified risk factors associated with recurrent ischemic events.
The primary endpoint rate reached 4.7% during the first year and increased continuously (by 4%-5% each year) to 17.6% by year 4, driven mainly by cardiovascular mortality (11.1% at year 4). Japan experienced lower adjusted ischemic rates (P < 0.01) vs North America. Renal impairment (P < 0.01), congestive heart failure (P < 0.01), history of diabetes (P < 0.01), history of myocardial infarction (P = 0.01), vascular disease (single or poly, P < 0.01), and older age (P < 0.01) were associated with increased risk of systemic ischemic events, whereas statin use was associated with lower risk (P = 0.03). The limb ischemic event rate was 5.7% at 2 years.
Four-year systemic ischemic risk in patients with PAD and no history of stroke or transient ischemic attack remains high, and was mainly driven by cardiovascular mortality.
有症状的外周动脉疾病(PAD)患者发生缺血性事件的风险很高。然而,关于这种风险预测因素的数据有限。
我们分析了国际持续健康动脉粥样硬化血栓形成减少(REACH)注册研究中纳入的有症状PAD且无卒中/短暂性脑缺血发作病史患者的基线特征和4年随访情况,以描述全球和各地区复发性缺血性事件的年发生率。
主要结局是4年时的全身性缺血性事件(心血管死亡、心肌梗死或卒中的复合事件)。次要结局是2年时的肢体缺血性事件(下肢截肢、外周旁路移植术和PAD的经皮介入治疗的复合事件)。多变量分析确定了与复发性缺血性事件相关的危险因素。
第一年主要终点发生率达到4.7%,并持续上升(每年上升4%-5%),到第4年升至17.6%,主要由心血管死亡率驱动(第4年为11.1%)。与北美相比,日本的校正缺血率较低(P<0.01)。肾功能损害(P<0.01)、充血性心力衰竭(P<0.01)、糖尿病病史(P<0.01)、心肌梗死病史(P=0.01)、血管疾病(单发或多发,P<0.01)和高龄(P<0.01)与全身性缺血性事件风险增加相关,而使用他汀类药物与较低风险相关(P=0.03)。2年时肢体缺血性事件发生率为5.7%。
无卒中或短暂性脑缺血发作病史的PAD患者4年全身性缺血风险仍然很高,且主要由心血管死亡率驱动。